Back to News
Market Impact: 0.1
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
Source: businesswire.com
Artificial IntelligenceHealthcare & BiotechTechnology & Innovation
Lantern Pharma announced that its Open-Medicine AI unit will present on the agentic AI drug-development market, user needs, platform economics, development roadmap, and benchmarking. The release contains no financial results, commercialization metrics, guidance changes, or quantified product milestones.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
LTRN0.35
More News
- China's AI chip blitz arms Xi with a message for Trump: 'You can't choke us off'
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- Meta announces new lightweight virtual reality glasses to one-up Apple’s Vision Pro
- US aviation sanctions disrupt Iran flights, push travellers overland
- Markets are rapidly coming around to the reality that the Fed has a lot more work to do
- Chinese authorities reportedly in possession of F-35 components in Hong Kong
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AlphaSense vs Hebbia vs AllMind: Choose by Workflow
- AllMind Discusses Ontario's AI Economy with Minister Stephen Crawford and Supply Ontario CEO James Wallace